Literature DB >> 23960233

B cells, dendritic cells, and macrophages are required to induce an autoreactive CD4 helper T cell response in experimental epidermolysis bullosa acquisita.

Hiroaki Iwata1, Katja Bieber, Benjamin Tiburzy, Navina Chrobok, Kathrin Kalies, Atsushi Shimizu, Sarah Leineweber, Akira Ishiko, Artem Vorobyev, Detlef Zillikens, Jörg Köhl, Jürgen Westermann, Karsten Seeger, Rudolf Manz, Ralf J Ludwig.   

Abstract

In autoimmune bullous dermatoses (AIBD), autoantibodies induce blisters on skin or mucous membranes, or both. Mechanisms of continued autoantibody production and blistering have been well characterized using AIBD animal models. Mechanisms leading to the initial autoantibody production, however, have not been investigated in detail. Epidermolysis bullosa acquisita (EBA) is an AIBD associated with autoantibodies to type VII collagen (COL7). The majority of EBA patients' sera recognize the noncollagenous domain 1, including the von Willebrand factor A-like domain 2 (vWFA2). In experimental EBA induced by immunization with GST-COL7, disease manifestation depended on the genetic background, a Th1 polarization, and the GST-tag. In this model, nude mice neither produced autoantibodies nor blisters. It has remained uncertain which APC and T cell subsets are required for EBA induction. We established a novel EBA model by immunization with vWFA2 fused to intein (lacking the GST-tag). All tested mouse strains developed autoantibodies, but blisters were exclusively observed in mice carrying H2s. In immunized mice, CD4 T cells specific for vWFA2 were detected, and their induction required presence of B cells, dendritic cells, and macrophages. Anti-vWFA2 autoantibodies located at the lamina densa bound to the dermal side of salt-split skin and induced blisters when transferred into healthy mice. Absence of CD8 T cells at time of immunization had no effect, whereas depletion of CD4 T cells during the same time period delayed autoantibody production and blisters. Collectively, we demonstrate the pathogenic relevance of Abs targeting the vWFA2 domain of COL7 and show the requirement of APC-induced CD4 T cells to induce experimental EBA.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23960233     DOI: 10.4049/jimmunol.1300310

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

1.  The cysteine-rich region of type VII collagen is a cystine knot with a new topology.

Authors:  Henrik Wegener; Hauke Paulsen; Karsten Seeger
Journal:  J Biol Chem       Date:  2014-01-02       Impact factor: 5.157

2.  Recombinant soluble CD32 suppresses disease progression in experimental epidermolysis bullosa acquisita.

Authors:  Hiroaki Iwata; Elena Pipi; Nicole Möckel; Peter Sondermann; Artem Vorobyev; Nina van Beek; Detlef Zillikens; Ralf J Ludwig
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

Review 3.  Mechanisms of Autoantibody-Induced Pathology.

Authors:  Ralf J Ludwig; Karen Vanhoorelbeke; Frank Leypoldt; Ziya Kaya; Katja Bieber; Sandra M McLachlan; Lars Komorowski; Jie Luo; Otavio Cabral-Marques; Christoph M Hammers; Jon M Lindstrom; Peter Lamprecht; Andrea Fischer; Gabriela Riemekasten; Claudia Tersteeg; Peter Sondermann; Basil Rapoport; Klaus-Peter Wandinger; Christian Probst; Asmaa El Beidaq; Enno Schmidt; Alan Verkman; Rudolf A Manz; Falk Nimmerjahn
Journal:  Front Immunol       Date:  2017-05-31       Impact factor: 7.561

4.  Autoantibodies to Multiple Epitopes on the Non-Collagenous-1 Domain of Type VII Collagen Induce Blisters.

Authors:  Artem Vorobyev; Hideyuki Ujiie; Andreas Recke; Jacqueline J A Buijsrogge; Marcel F Jonkman; Hendri H Pas; Hiroaki Iwata; Takashi Hashimoto; Soo-Chan Kim; Jong Hoon Kim; Richard Groves; Unni Samavedam; Yask Gupta; Enno Schmidt; Detlef Zillikens; Hiroshi Shimizu; Ralf J Ludwig
Journal:  J Invest Dermatol       Date:  2015-02-17       Impact factor: 8.551

5.  Effects of intravenous immunoglobulins on mice with experimental epidermolysis bullosa acquisita.

Authors:  Misa Hirose; Benjamin Tiburzy; Norito Ishii; Elena Pipi; Sabina Wende; Ellen Rentz; Falk Nimmerjahn; Detlef Zillikens; Rudolf A Manz; Ralf J Ludwig; Michael Kasperkiewicz
Journal:  J Invest Dermatol       Date:  2014-10-20       Impact factor: 8.551

6.  Reduced skin blistering in experimental epidermolysis bullosa acquisita after anti-TNF treatment.

Authors:  Misa Hirose; Anika Kasprick; Foteini Beltsiou; Katharina Dieckhoff Schulze; Franziska Sophine Schulze; Unni Kjsrl Samavedam; Jennifer E Hundt; Hendri H Pas; Marcel F Jonkman; Enno Schmidt; Kathrin Kalies; Detlef Zillikens; Ralf J Ludwig; Katja Bieber
Journal:  Mol Med       Date:  2016-12-20       Impact factor: 6.354

7.  Hair follicle stem cell progeny heal blisters while pausing skin development.

Authors:  Yu Fujimura; Mika Watanabe; Kota Ohno; Yasuaki Kobayashi; Shota Takashima; Hideki Nakamura; Hideyuki Kosumi; Yunan Wang; Yosuke Mai; Andrea Lauria; Valentina Proserpio; Hideyuki Ujiie; Hiroaki Iwata; Wataru Nishie; Masaharu Nagayama; Salvatore Oliviero; Giacomo Donati; Hiroshi Shimizu; Ken Natsuga
Journal:  EMBO Rep       Date:  2021-06-04       Impact factor: 9.071

Review 8.  Advances in understanding and treating dystrophic epidermolysis bullosa.

Authors:  Michael J Vanden Oever; Jakub Tolar
Journal:  F1000Prime Rep       Date:  2014-05-06

9.  T cells mediate autoantibody-induced cutaneous inflammation and blistering in epidermolysis bullosa acquisita.

Authors:  Katja Bieber; Mareike Witte; Shijie Sun; Jennifer E Hundt; Kathrin Kalies; Sören Dräger; Anika Kasprick; Trix Twelkmeyer; Rudolf A Manz; Peter König; Jörg Köhl; Detlef Zillikens; Ralf J Ludwig
Journal:  Sci Rep       Date:  2016-12-05       Impact factor: 4.379

10.  Therapeutic Effect of a Novel Phosphatidylinositol-3-Kinase δ Inhibitor in Experimental Epidermolysis Bullosa Acquisita.

Authors:  Hiroshi Koga; Anika Kasprick; Rosa López; Mariona Aulí; Mercè Pont; Núria Godessart; Detlef Zillikens; Katja Bieber; Ralf J Ludwig; Cristina Balagué
Journal:  Front Immunol       Date:  2018-07-12       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.